Ipamorelin vs CJC-1295: Two Routes Into the Growth-Hormone Axis

Ipamorelin and CJC-1295 are routinely shelved side by side, and the reason is more interesting than the resemblance suggests: they reach the same endocrine axis from opposite ends. One impersonates ghrelin; the other impersonates growth-hormone-releasing hormone (GHRH). That single fact — two molecules, two receptors, one pathway — explains why they are among the most-studied reference compounds in growth-hormone-axis research, and why a serious comparison is worth more than a feature list. What follows treats their chemistry, receptor mechanisms, and the published preclinical literature strictly within a research-use-only (RUO) framework. Nothing here describes human use, dosing, or therapeutic outcomes.

What is the core difference between Ipamorelin and CJC-1295?

They are not two flavours of the same thing; they belong to different chemical and mechanistic classes. Ipamorelin is a small synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), characterised in its founding study as the first selective growth-hormone secretagogue acting at the ghrelin receptor, GHS-R1a.¹ CJC-1295 (no DAC) — also called Modified GRF(1-29) — is a 29-amino-acid analogue of the bioactive N-terminal fragment of GHRH, engineered with substitutions (notably D-Ala at position 2) that blunt enzymatic degradation while preserving GHRH-receptor recognition.

Reduced to its essentials: in experimental systems, Ipamorelin is studied as a ghrelin mimetic and CJC-1295 as a GHRH mimetic. Because they engage distinct receptors, researchers have asked how the two stimuli interact at the pituitary — the rationale behind the co-formulated CJC-1295 (no DAC) + Ipamorelin research blend.

711.85 vs 3367.9 g/mol separates the two by an order of magnitude in molecular mass — a five-residue pentapeptide against a 29-residue GHRH analogue — a useful reminder that “same axis” does not mean “same molecule.”

How do their mechanisms compare in the literature?

Ipamorelin made its name on selectivity. In the founding study it raised growth hormone in animal models with minimal accompanying release of ACTH or cortisol, a clean profile that set it apart from older growth-hormone-releasing peptides such as GHRP-6.¹ Its pharmacokinetics were later characterised alongside other peptidyl secretagogues, where it showed markedly lower systemic clearance than GHRP-6.² The story does not end at the GH axis: as a ghrelin mimetic, Ipamorelin has also been examined in rodent gastrointestinal-motility paradigms, including a postoperative-ileus model.³

CJC-1295 works upstream, on the GHRH receptor. Animal and analytical work documents activation of the GH/IGF-1 axis and accompanying changes in serum protein profiles,⁷ and a knockout-mouse study reported normalised growth with infrequent dosing.⁸ But the defining theme of the CJC-1295 record is duration. An early human proof-of-concept study reported prolonged elevation of GH and IGF-1,⁵ while a separate study found that GH secretion remained pulsatile even under continuous stimulation⁶ — a subtle but important point, since sustained receptor drive does not necessarily flatten the axis’s native rhythm.

Two molecules, two receptors, one pathway: Ipamorelin pushes from the ghrelin side, CJC-1295 from the GHRH side, which is precisely why researchers study them together.

DAC vs no-DAC: why does CJC-1295 come in two forms?

This is the distinction most often muddled, and it is purely one of duration. The no-DAC form is the lighter, shorter-acting Modified GRF(1-29) peptide. The DAC form adds a Drug Affinity Complex — a maleimidopropionyl group that binds covalently to circulating serum albumin, dramatically extending circulating residence. The foundational demonstration showed that hGRF(1-29)-albumin bioconjugates activate the GRF receptor and identified CJC-1295 itself as a long-lasting GRF analogue.⁴ For head-to-head work with Ipamorelin, the no-DAC form is the more natural counterpart, because its kinetics sit on a comparable timescale.

How do the specifications compare at a glance?

Side-by-side reference specifications for Ipamorelin and CJC-1295 (no DAC), as supplied for research use only.

What does the evidence actually support — preclinical or clinical?

Honesty about the evidence base is the point at which most comparisons quietly fail, so it is worth being blunt. The bulk of the literature for both compounds is preclinical — in vitro and animal studies. Ipamorelin’s core characterisations are animal and pharmacokinetic in nature,¹²³ and it has not progressed to any established clinical indication. CJC-1295 sits slightly further along, with a small number of early human reports describing GH/IGF-1 responses and secretory dynamics,⁵⁶ set against its animal and analytical work.⁷⁸⁴ These early studies describe biological activity in experimental settings; they do not establish efficacy or safety for any human or veterinary application. Neither compound is an approved drug. Both are growth-hormone secretagogues and are, as a matter of regulatory fact, prohibited in sport under the World Anti-Doping Agency framework — a status worth noting precisely because it is so often elided.

Which is “better” for a given research question?

The honest answer is that there is no general “better” — the choice follows the experimental question, not any consumer outcome. A study probing the ghrelin receptor, GI motility, or selective secretagogue behaviour points toward Ipamorelin. A study probing GHRH-receptor signalling, IGF-1 dynamics, or duration-of-action chemistry points toward CJC-1295 — no DAC for shorter kinetics, DAC for extended albumin-bound residence. Researchers investigating how the two stimuli converge at the pituitary often reach for both together via the co-formulated blend. In every case the work is restricted to qualified professionals in an appropriately equipped laboratory and is for research use only.

Both products are supplied strictly for laboratory research use only (RUO). They are characterised at ≥99% purity by HPLC, third-party tested, and ship with a Certificate of Analysis (COA). They are not drugs, foods, cosmetics, or dietary supplements, and are not for human or veterinary use, ingestion, or diagnostic application.